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Rapid, simple, and accurate antemortem tests for tuberculosis (TB) in cattle need to be developed in order
to augment the existing screening methods. In particular, as cattle vaccines are developed, such tests would
allow the continuation of test-and-slaughter policies alongside vaccination. Therefore, the development of an
assay that distinguishes infected from vaccinated animals (a DIVA test) is an urgent research requirement. In
this study, we assessed the performance of a novel multiplex serological test with sera collected from 96
skin-tested animals with bovine tuberculosis, 93 TB-free animals, and 39 cattle vaccinated with Mycobacterium
bovis BCG. Our results indicate that the test has a relative sensitivity range of 77.0% to 86.5% at corresponding
specificity levels of 100.0% to 77.6%. Comparison with the Bovigam gamma interferon antemortem test revealed
that this serology test was significantly more sensitive at specificities above 97.9%, while the Bovigam test was,
on average, about 10% more sensitive when the test specificity was set below 97%. Importantly, this serological
multiplex assay does not react with sera from BCG-vaccinated calves and is therefore suitable as a DIVA test
alongside BCG-based vaccine strategies.
Bovine tuberculosis (bTB) is a zoonotic disease caused by
the bacterial pathogen Mycobacterium bovis. Although the
main host is cattle, M. bovis can infect many species, including
wildlife and humans. In developed countries where the con-
trol and eradication of bTB continue to be a problem, the
impact of bTB on the farming community and government
control agencies is primarily of economic significance (1, 20;
http://www.defra.gov.uk/foodfarm/farmanimal/diseases/atoz/tb
/documents/expenditure-stats.pdf). However, in the presence
of wildlife reservoirs, such as the possum in New Zealand or
the badger in Great Britain and Ireland, bTB has been difficult
to eradicate. The primary bTB screening and control tool is the
tuberculin skin test (TST), with the removal of animals found
to be positive (reactors). The TST as applied in Great Britain
and Ireland is called the single intradermal comparative cer-
vical tuberculin test (SICCT) (14). It involves the injection of
bovine tuberculin (a purified protein derivative [PPD] pre-
pared from M. bovis strain AN5) and PPD tuberculin from
Mycobacterium avium into the skin of the neck. Animals with
bovine PPD (PPD-B)-biased responses are then removed.
A widely used ancillary in vitro test for TB is a gamma
interferon (IFN-) release assay (IGRA) that also employs
avian and bovine tuberculin (Bovigam) (18, 28, 30). Both the
TST and the Bovigam assay probe cell-mediated immune
(CMI) responses (16). Questions have been raised with regard
to both the sensitivity (proportion of true positives) and spec-
ificity (proportion of true negatives) of tuberculin-based tests,
for example, for herds that are coinfected with Mycobacterium
avium subsp. paratuberculosis (2, 3), or in the context of vaccine
strategies under development that involve the use of M. bovis
bacillus Calmette-Gue´rin (BCG) (4, 23, 24). Therefore, re-
search has been directed toward the diagnosis of bTB using
specific and defined antigens that will improve test specificity
and enable tests to function as DIVA tests. This has been
particularly successful when such antigens are used in combi-
nation with IGRAs as DIVA tests (5, 8, 19, 23, 25).
Serological tests have logistical and financial advantages
over assays based on cell-mediated immunity. Yet in the past
they have suffered from relatively poor sensitivity (26, 29, 31)
and therefore were not considered the method of choice for
the delivery of highly sensitive tests for bTB. However, recent
advances in antigen discovery and the development of novel
and more-sensitive detection systems have led to serological
assays that show promise in delivering highly sensitive tests (10,
27). One recently described assay (the Enferplex TB assay) is
a chemiluminescent multiplex system that can simultaneously
detect and analyze antibody responses to multiple antigens
spotted in a single well of a 96-well plate (27). The sensitivity
and specificity of the Enferplex TB assay have been reported as
93.1% and 98.4%, respectively, in a nonblinded Irish study
(27).
The present study was conducted to extend these findings by
determining the relative sensitivity and specificity of the En-
ferplex TB serum assay in comparison to those of the SICCT
and the Bovigam IGRA in a blinded study with serum samples
from cattle from Great Britain with and without bTB. In con-
trast to the method of another study (T. Clegg, A. Duignan, C.
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More, submitted for publication), which assessed nonoverlap-
ping populations by latent class analysis to compare tests, the
same animals in the present study were tested with the Enfer-
plex TB assay, the SICCT, and the Bovigam IGRA (a subset of
30 only). Further, we assessed the performance of this serological
assay as a DIVA test compared to those of the SICCT and the
Bovigam IGRA by using sera from BCG-vaccinated cattle.
MATERIALS AND METHODS
Serum samples. Serum samples were collected from 96 SICCT-positive cattle
from herds in Great Britain with known bTB incidence. All animals presented
with visible lesions typical of bTB at slaughter and were culture positive. These
animals were sampled as part of two studies funded by the Department for
Environment, Food and Rural Affairs (Defra) (SE3013 and SE3227). In addi-
tion, 93 sera were collected from skin test-negative animals from herds with no
recent TB history located in regions of Great Britain where bTB is not endemic.
A group of 39 male calves (Holstein or Holstein crosses) were neonatally vac-
cinated with a Danish BCG strain (Statens Serum Institut, Copenhagen, Den-
mark), and serum was collected 6 months postvaccination. Serum samples from
all animal groups were drawn between 2 and 5 weeks after the SICCT was
performed.
A further group of 21 animals, composed of Holstein or Holstein-cross male
calves, was experimentally infected via the intratracheal route with 2,000 CFU of
the Great Britain M. bovis field isolate AF2122/97. The animals were approxi-
mately 6 months old at the time of infection, and monthly serum samples were
collected over a 16-week period. All animals presented with visible lesions and
were culture positive when postmortem examinations were carried out, 17 weeks
postinfection.
Project license. All animal experimentation was carried out under a Great
Britain Home Office animal project license granted under the Animals (Scientific
Procedures) Act of 1984. This project license was approved by the local Ethical
Review Board before its submission to the Home Office.
Enferplex TB serum assay. The multiplex immunoassay (Enferplex TB assay;
Enfer Scientific, Naas, County Kildare, Ireland) was conducted using methods
described previously (27). Briefly, a multiplex chemiluminescent immunoassay
was developed to simultaneously detect antibody recognition of as many as 25
antigens in a single well in a 96-well plate array format. In this assay, the
chemiluminescent signal is captured with a digital imaging system and is analyzed
with bespoke software based on Excel (Enfer Scientific) that tracks each serum
sample for its pattern of antibody recognition of M. bovis antigens. Samples of
known provenance were used to set different levels of specificity and sensitivity
based on patterns of antibody recognition. Five different cutoff levels with dif-
ferent sensitivities and specificities were used in the current study (Enferplex TB
cutoff levels 1 to 5).
Bovigam IGRA. Blood was collected from a subset of 30 of the cattle with bTB,
and the Bovigam IGRA was performed as in the routine application of this test
in Great Britain. Briefly, heparinized blood was collected, and whole blood
cultures were initiated on the day following sampling. Blood cells were stimu-
lated with avian and bovine PPDs (Veterinary Laboratories Agency [VLA]—
Weybridge, Addlestone, United Kingdom) at concentrations of 10 g/ml. Only
results that met the positive-control criteria were used (optical density at 450 nm
[OD450], 0.5 by use of staphylococcal enterotoxin B [Sigma-Aldrich, Poole,
United Kingdom] at 1 g/ml). Plasma supernatants were harvested 20 to 24 h
later, and the IFN- contents of the supernatants were determined with the
Bovigam IFN- kit (Prionics, Schlieren, Switzerland) according to the manufac-
turer’s instructions. Cutoffs at specificity levels corresponding to those calculated
for the different interpretations of the Enferplex TB assay were obtained for the
Bovigam IGRA by using receiver operating characteristic (ROC) curve analysis
as described elsewhere (21a). ROC curves are graphical plots of sensitivity versus
(1  specificity) for a binary classifier system as its discrimination threshold is
varied, and they can be used to select optimal cutoffs for test positivity.
Statistical analysis. The performances of the IGRA and the multiplex assay
were compared using either the Mann-Whitney test or Fisher’s exact test with
significance levels set at 5%. Analysis was performed using Instat, version 3
(GraphPad, San Diego, CA).
RESULTS AND DISCUSSION
Sera from 189 animals (96 SICCT reactor animals with vis-
ible tuberculous lesions and culture-confirmed bTB; 93 bTB-
free animals) were analyzed using the Enferplex TB assay. The
disease statuses of these animals were unknown to the opera-
tors of the test, and the code was broken only after the test
results were interpreted. Five interpretation criteria represent-
ing increasing specificity settings were applied. The results
shown in Table 1 demonstrated the high accuracy of the test,
with relative sensitivities ranging from 86.5% at the lowest
specificity setting of 79.6% (Enferplex TB cutoff level 1) to
77.1% at the most stringent specificity setting (100% [Enfer-
plex TB cutoff level 5]).
The sensitivity of the test in this study is significantly lower at
comparable specificity levels than the sensitivity obtained in
the study testing Irish cattle that was previously reported by
Whelan et al. in 2008 (27) (79.2% versus 93.1% at specificities
of 97.9 and 98.4%, respectively; P, 0.0001 by Fisher’s exact
test). The difference in sensitivity could be due to a different
disease status of the Irish cattle, to differences in populations,
or to the fact that the samples in the present study were drawn
after skin test injection. However, the latter hypothesis does
not agree with published data demonstrating that tuberculin
injection boosts serum responses, thus increasing test sensitiv-
ity (12, 13, 26).
For a subset of 30 cattle with bTB, corresponding Bovigam
IGRA data were available. The IGRA was performed accord-
ing to the routine application of this assay in Great Britain as
an ancillary test to the SICCT (http://www.defra.gov.uk
/foodfarm/farmanimal/diseases/atoz/tb/control/gamma-criteria
.htm). To allow a full comparison between the tests, we used
ROC analysis of a Bovigam test data set from 1,198 cattle,
available through the various Great Britain validation studies
undertaken since 2002 (21a). This was used to determine the
Bovigam test cutoffs that corresponded to the 5 multiplex test
specificity settings shown in Table 1. Using these cutoffs,
relative sensitivity rates were calculated for the Bovigam assay
by subtracting the OD450 obtained with the avian PPD (PPD
-A) from the OD450 obtained with the bovine PPD, and these
were compared to the corresponding results obtained with sera
from these 30 cows in the multiplex assay. In addition, we
included the relative Bovigam sensitivity for these animals at
the specificity setting used in the routine Bovigam assay in
Great Britain (approximately 97% [25a]). As the data in Fig. 1
indicate, the Bovigam IGRA was about 10% more sensitive
than the serology test up to specificity settings of 97%. This
difference was significant at these specificities (P, 0.05 by the
Mann-Whitney test). However, if the specificity was maximized
to 100%, the Enferplex TB immunoassay was significantly
TABLE 1. Performance of the Enferplex TB multiplex
immunoassay on field animals
Enferplex TB
cutoff level Sensitivity
a Specificityb
5 77.1 (67.4, 85.0) 100 (96.1, 100)
4 79.2 (69.7, 86.8) 97.9 (92.4, 99.7)
3 81.3 (72.0, 88.5) 94.6 (87.9, 98.2)
2 82.3 (73.1, 89.3) 91.4 (83.8, 96.2)
1 86.5 (78.0, 92.6) 79.6 (70.0, 87.23)
a Measured for 96 SICCT reactor animals, with visible lesions and positive M.
bovis cultures. Both sensitivity and specificity are expressed as percentages, with
95% confidence intervals in parentheses.
b Measured for 93 skin test-negative cattle from TB-free herds.
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more sensitive than the IGRA (33% versus 73.3%,
respectively; P, 0.004 by Fisher’s exact test). Therefore, the
present data demonstrate that the Enferplex TB immunoassay can
be optimized to address particular surveillance requirements to a
degree that the Bovigam IGRA cannot. However, the data also
demonstrate that cell-mediated tests provide sensitivity
advantages when lower specificity values are acceptable, thus
maximizing the number of diseased animals that can be
detected.
Next, we assessed the performance of the multiplex assay for
its potential as a DIVA test and compared it to the Bovigam
IGRA and the SICCT (Table 2). Sera from 39 animals vacci-
nated neonatally with BCG were collected about 6 months
postvaccination. None of these sera yielded a positive result
with the Enferplex TB assay at any of the 5 specificity settings
(Table 2). The results show that the Enferplex TB assay has
potential as a DIVA test in the context of BCG vaccination
based on the samples investigated. However, further studies
need to be conducted in order to determine the degree to
which our findings can be extrapolated to the wider population.
In contrast, 66.6% (26/39) of the calves tested positive with the
SICCT when the standard interpretation criteria (bovine PPD
response minus avian PPD response, 4 mm) were used, and
87.2% (34/39) tested positive when the severe SICCT interpre-
tation criteria (bovine minus avian PPD response, 2 mm)
were applied (Table 2). We also performed an IGRA in order
to obtain comparative test information. With the Bovigam
IGRA, 38.5% (15/39) of these animals tested positive by using
an OD450 differential (bovine minus avian PPD) of 0.1 as the
cutoff for positivity (Table 2), confirming that the specificity of
tuberculin-based tests is compromised after BCG vaccination.
DIVA reagents based on the Bovigam IGRA are currently
being developed and include antigens such as ESAT-6 and
CFP-10, whose genes are deleted from the genome of BCG (5,
15, 21, 24). When we used these two antigens in the form of a
synthetic peptide pool in the Bovigam assay (22) for these 39
animals, we found weak but positive responses for 7.7% (3/39)
of the BCG-vaccinated animals by using an OD450 differential
of 0.1 (ESAT-6/CFP-10 minus medium only) as the cutoff
(Table 2). Thus, the Enferplex TB assay is at least as specific a
DIVA test as the Bovigam IGRA with ESAT-6 and CFP-10.
When we calculated the sensitivity of the Bovigam assay rela-
tive to that of the SICCT for the 30 animals with bTB assessed
as described above by using ESAT-6 and CFP-10 as IGRA
antigens, we found that it was lower than that of the Enferplex
TB assay at a comparable specificity level of 97% (73.3%
[22/30] versus 78% [25/30]), although this difference was not
statistically significant. We have recently identified another
IGRA antigen that complemented ESAT-6 and CFP-10 as a
DIVA reagent by increasing the sensitivity of the test to levels
comparable to those achieved with PPD (19), and it will be of
interest to compare these improved IGRA DIVA reagents
with the Enferplex TB serum assay in future studies.
However, in considering the specificities of the Bovigam test,
it should be noted that these BCG vaccinees were close to the
minimum eligibility cutoff age of 6 months for standard IGRA
application. Thus, at least some of these responses were likely
due to nonspecific (natural killer [NK]) cell activity, described
previously (14), resulting in false-positive responses for these
young animals. In Great Britain, cattle younger than 6 months
are excluded from Bovigam testing in order to minimize the
risk of such nonspecific IFN- production. It appears that the
multiplex assay is generally less affected by this nonspecific
reactivity and could therefore be used for this age group. The
higher specificity of the Enferplex TB assay across all interpre-
tation criteria for the BCG vaccinee cohort than for the TB-
free field animals (Table 1) is likely due to the fact that the
former animals are younger and were kept from birth under
laboratory conditions that prevented exposure to environmen-
tal bacteria that could affect test specificity.
Interestingly, when we compared the response kinetics of
the IGRA and the serum responses measured by the multiplex
assay using sera from experimentally infected animals, we
found that all 21 animals tested IGRA positive (using an OD
difference [bovine minus avian PPD] of 0.1 as a cutoff) 4
TABLE 2. Evaluation of the DIVA potential of the
Enferplex TB assaya
Test performed
% of
animals testing
positive (95% CIb)
No. of
animals testing
positive/total no.
Pc
Enferplex TBd 0 (0, 9) 0/39 NA
SICCT
Standard interpretation 66.6 (49.8, 80.9) 26/39 0.0001
Severe interpretation 87.2 (72.5, 95.7) 34/39 0.0001
Bovigam IGRAe
PPD-B and -A 38.5 (23.4, 55.4) 15/39 0.0001
ESAT-6 and CFP-10 7.7 (1.6, 20.8) 3/39 0.2403
a Calves were neonatally vaccinated with BCG, and serum samples were col-
lected 6 months postvaccination and 2 to 5 weeks after the SICCT was per-
formed.
b CI, confidence interval.
c For comparison of the SICCT or the Bovigam IGRA to the Enferplex TB
assay by Fisher’s exact test. To account for multiple-comparison errors, a P value
smaller than 0.0125 was used to define statistical significance. NA, not applicable.
d Animals tested negative with all 5 of the interpretation criteria.
e For the Bovigam IGRA, the cutoff was a difference of 0.1 OD450 unit
between the PPD-B and PPD-A results or between the results with the cocktail
of ESAT-6- and CFP-10-derived synthetic peptides and the results with the
no-antigen control.
FIG. 1. Comparison of the sensitivities of the Bovigam IGRA and
the Enferplex TB multiplex immunoassay. The analysis is based on the
testing of 30 animals with confirmed bTB. The interpretation of the
Bovigam assay is based on the differences between the OD450 values
obtained after stimulation with bovine versus avian PPD. The follow-
ing cutoffs were used to determine the relative sensitivity of the Bo-
vigam IGRA: 79.6% specificity corresponds to a difference of 0.016
OD450 unit; 91.4% specificity, to a 0.045-OD450 difference; 94.6%
specificity, to a 0.076-OD450 difference; 97% specificity, to a 0.110-
OD450 difference; 97.8% specificity, to a 0.178-OD difference; and
100% specificity, to a 1.903-OD450 difference.
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weeks postinfection, while serum responses took longer to
develop, with only about 43% (9/21) of infected calves giving
positive responses at 12 weeks postinfection (Fig. 2; specificity
setting, level 4, as shown in Table 1). While these results are in
agreement with other observations that suggest a spectral dis-
ease progression of bTB in cattle (17), with cellular immune
responses developing before humoral responses, the present
finding is in contrast to that of an earlier study indicating that
experimentally infected cattle could be detected as early as 5
weeks postinfection by this assay (27). However, different chal-
lenge inocula were used in the two experiments, as well as
different challenge strains. Therefore, the two data sets are not
directly comparable.
Our study is limited to some degree in that all our samples
were collected from cattle that underwent tuberculin skin test-
ing prior to sampling. The sensitivity estimates reported in
Table 1 for the Enferplex TB assay are, therefore, potentially
biased (overestimated), since skin test positivity was used as
the initial selection criterion for infected cattle. Several studies
have shown that the skin test boosts serum antibody responses
and consequently increases sensitivity (11–13, 26). In contrast,
IFN- production is little affected by skin testing when the
SICCT is used (7, 9), although IFN- responses have been
shown to be boosted following the caudal fold tuberculin test
(6, 30). Therefore, further studies are needed to assess whether
prior skin testing will affect sensitivity. However, if the Enfer-
plex TB assay is used as an ancillary test to the skin test, like
the Bovigam IGRA, this consideration will be less relevant. In
this scenario, further studies have to be performed with dis-
eased animals that escape detection by skin testing, since such
animals would be the primary target population for any ancil-
lary test. The Bovigam IGRA is used predominantly in this
way, and our data from a recent study demonstrated that the
sensitivities of the Bovigam IGRA (PPD-B minus PPD-A re-
sults) are identical for animals with confirmed bTB in SICCT-
positive and SICCT-negative populations (89.72% and
91.36%, respectively, at 96.5% specificity [21a]). The use of
both tests together in parallel, therefore, significantly increases
the proportion of diseased animals that are detected, and one
would expect a similar outcome by using the Enferplex TB
assay in combination with skin tests and/or IGRAs. However,
further comparative test validations are required in order to
fully appreciate whether the multiplex serology assay can be
used alone as a DIVA test or whether it must be used in
combination with the tests probing cell-mediated immunity
(the skin test and the Bovigam IGRA) in order to maximize
sensitivity and specificity.
In conclusion, the present study has reaffirmed the high
sensitivity (77%) of the Enferplex TB assay, even at maximal
specificity levels. Furthermore, our study also demonstrated
that the Enferplex TB assay would have considerable logistical
advantages over blood tests using cellular immunity as a read-
out and could therefore contribute to the cost-effective appli-
cation of a cattle vaccination policy. Furthermore, it could
potentially be used in combination with other antemortem
tests, the SICCT and the Bovigam IGRA, as part of a diag-
nostic program aimed at detecting animals at different disease
stages.
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